Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma - PubMed (original) (raw)
. 2017 Oct 1;23(19):5959-5969.
doi: 10.1158/1078-0432.CCR-17-0256. Epub 2017 Jun 9.
Kamila Naxerova 1, Matthias Pinter 1, Joao Incio 1, Hang Lee 3, Kohei Shigeta 1, William W Ho 1 4, Jonathan A Crain 1, Alex Jacobson 5, Theodoros Michelakos 6, Daniella Dias-Santos 6, Andrea Zanconato 6, Theodore S Hong 7, Jeffrey W Clark 8, Janet E Murphy 8, David P Ryan 8, Vikram Deshpande 9, Keith D Lillemoe 6, Carlos Fernandez-Del Castillo 6, Michael Downes 10, Ronald M Evans 10, James Michaelson 5, Cristina R Ferrone 6, Yves Boucher 11, Rakesh K Jain 11
Affiliations
- PMID: 28600474
- PMCID: PMC5856249
- DOI: 10.1158/1078-0432.CCR-17-0256
Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma
Hao Liu et al. Clin Cancer Res. 2017.
Abstract
Purpose: Angiotensin system inhibitors (ASI) can improve prognosis in multiple cancer types, including pancreatic ductal adenocarcinoma (PDAC). However, no study has examined the effect of ASIs alone or combined with adjuvant chemotherapy in resected PDAC patients.Experimental Design: We performed an analysis of the records of ASI users and nonuser patients with PDAC seen at Massachusetts General Hospital (Boston, MA) between January 2006 and December 2010. To identify mechanisms of ASIs in PDAC, we performed RNA sequencing (RNA-Seq) of resected primary lesions.Results: A total of 794 consecutive patients were included. In 299 resected patients, ASI users experienced longer overall survival (OS) in both univariate (median OS, 36.3 vs. 19.3 months, P = 0.011) and adjusted multivariate [HR, 0.505; 95% confidence interval (CI), 0.339-0.750; P = 0.001] analyses. Propensity score-adjusted analysis also showed a longer median OS for chronic ASI users. In unresected patients, the beneficial effect of ASIs was significant in patients with locally advanced disease, but not in metastatic patients. RNA-Seq analysis revealed in tumors of ASI users (lisinopril) a normalized extracellular matrix, a reduced expression of genes involved in PDAC progression (e.g., WNT and Notch signaling), and an increased expression of genes linked with the activity of T cells and antigen-presenting cells. Finally, chronic use of ASI was associated with a gene expression signature that is predictive of survival in independent validation cohorts.Conclusions: In patients with nonmetastatic PDAC, chronic ASI use is associated with longer OS independently of chemotherapy. Our RNA-Seq analysis suggests that ASIs reduce the malignant potential of cancer cells and stimulate the immune microenvironment in primary PDAC. Clin Cancer Res; 23(19); 5959-69. ©2017 AACR.
©2017 American Association for Cancer Research.
Conflict of interest statement
Conflict of Interest Disclosure statement: R.K.J. received consultant fees from Ophthotech, SPARC, SynDevRx and XTuit. R.K.J owns equity in Enlight, SPARC, SynDevRx and XTuit, and serves on the Board of Directors of XTuit and Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. Y.B. received consultant fees from XTuit. M.P. received travel grants and speaker fees from Bayer. No reagents or funding from these companies were used in these studies. R.K.J only had access to de-identified data.
Figures
Figure 1. Unadjusted Kaplan Meier curves for overall survival in metastatic (A), locally advanced (B) and resected (C) patients. HR = Hazards ratio
Figure 2
A: Number of GO, BIOCARTA, KEGG, PID, and REACTOME gene sets that are significantly changed (FDR<0.05) in our GSEA analysis, grouped by biological function. (Complete GSEA results are shown in Supplementary Table 9). Gene Set Enrichment Analysis (GSEA) of human PDAC comparing ACEi treated tumors vs. control tumors. B: Decrease in the activity of integrin beta 3, NOTCH, WNT and the cell cycle. C: Increase in oxidative phosphorylation, improvement in lipid metabolism, PPAR signaling, and adaptive immune response. D: Increase in cytotoxic activities, immuno-synapse and antigen presentation pathways (Detailed enrichment score in Supplementary Table 11).
Figure 3
Kaplan Meier analysis on ASI down regulated gene pathway and overall survival. ASI low pathway expression level: 1 = low, 2 = med, 3 = high. A: UNC dataset. B: TCGA dataset, overall survival. UNC Dataset overall Kaplan Meier analysis p=0.017, HR =0.513, 95% CI = 0.292 - 0.900. TCGA Dataset overall Kaplan Meier analysis p=0.002, HR =0.422, 95% CI = 0.248 - 0.718.
Similar articles
- Correlation between Angiotensin Inhibitor Administration and Longer Survival in Patients Who Underwent Curative Resection for Pancreatic Cancer.
Yang HY, Kang MY, Kang CM, Lee WJ, Hwang HK. Yang HY, et al. Yonsei Med J. 2024 Jun;65(6):324-331. doi: 10.3349/ymj.2023.0399. Yonsei Med J. 2024. PMID: 38804026 Free PMC article. - The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients.
Liu H, Nassour I, Lebowitz S, D'Alesio M, Hampton E, Desilva A, Hammad A, AlMasri S, Khachfe HH, Singhi A, Bahary N, Lee K, Zureikat A, Paniccia A. Liu H, et al. HPB (Oxford). 2023 Mar;25(3):320-329. doi: 10.1016/j.hpb.2022.12.002. Epub 2022 Dec 14. HPB (Oxford). 2023. PMID: 36610939 Free PMC article. - Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R, Liu X, Liang C, Hua J, Xu J, Wang W, Meng Q, Liu J, Zhang B, Yu X, Shi S. Tang R, et al. Front Immunol. 2021 Mar 10;12:648917. doi: 10.3389/fimmu.2021.648917. eCollection 2021. Front Immunol. 2021. PMID: 33777046 Free PMC article. - Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.
Knudsen ES, Vail P, Balaji U, Ngo H, Botros IW, Makarov V, Riaz N, Balachandran V, Leach S, Thompson DM, Chan TA, Witkiewicz AK. Knudsen ES, et al. Clin Cancer Res. 2017 Aug 1;23(15):4429-4440. doi: 10.1158/1078-0432.CCR-17-0162. Epub 2017 Mar 27. Clin Cancer Res. 2017. PMID: 28348045 Free PMC article. - Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications.
Martens S, Lefesvre P, Nicolle R, Biankin AV, Puleo F, Van Laethem JL, Rooman I. Martens S, et al. Ann Oncol. 2019 Sep 1;30(9):1428-1436. doi: 10.1093/annonc/mdz181. Ann Oncol. 2019. PMID: 31161208 Review.
Cited by
- Role of renin angiotensin system inhibitors and metformin in Glioblastoma Therapy: a review.
Dixon S, O'connor AT, Brooks-Noreiga C, Clark MA, Levy A, Castejon AM. Dixon S, et al. Cancer Chemother Pharmacol. 2024 Jul;94(1):1-23. doi: 10.1007/s00280-024-04686-0. Epub 2024 Jun 25. Cancer Chemother Pharmacol. 2024. PMID: 38914751 Review. - Correlation between Angiotensin Inhibitor Administration and Longer Survival in Patients Who Underwent Curative Resection for Pancreatic Cancer.
Yang HY, Kang MY, Kang CM, Lee WJ, Hwang HK. Yang HY, et al. Yonsei Med J. 2024 Jun;65(6):324-331. doi: 10.3349/ymj.2023.0399. Yonsei Med J. 2024. PMID: 38804026 Free PMC article. - The concomitant use of the renin-angiotensin system inhibitors and survival outcomes of patients with pancreatic adenocarcinoma: an analysis from a tertiary center.
Tseng KY, Hsu CY, Shih YH, Lin HC, Li YC, Jerry Teng CL, Chou CW. Tseng KY, et al. Ther Adv Med Oncol. 2024 May 6;16:17588359241247019. doi: 10.1177/17588359241247019. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38716478 Free PMC article. - Cancer and Cardiovascular Disease: The Conjoined Twins.
Zmaili M, Alzubi J, Alkhayyat M, Albakri A, Alkhalaileh F, Longinow J, Moudgil R. Zmaili M, et al. Cancers (Basel). 2024 Apr 9;16(8):1450. doi: 10.3390/cancers16081450. Cancers (Basel). 2024. PMID: 38672532 Free PMC article. Review. - Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials.
Benjamin DJ, Haslam A, Prasad V. Benjamin DJ, et al. Cancer Med. 2024 Mar;13(5):e7049. doi: 10.1002/cam4.7049. Cancer Med. 2024. PMID: 38491813 Free PMC article.
References
- George AJ, Thomas WG, Hannan RD. Nat Rev Cancer. Vol. 10. Nature Publishing Group; 2010. The renin–angiotensin system and cancer: old dog, new tricks; pp. 745–59. - PubMed
- Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Research. 2000;60:2497–503. - PubMed
MeSH terms
Substances
Grants and funding
- R35 CA197743/CA/NCI NIH HHS/United States
- P01 CA080124/CA/NCI NIH HHS/United States
- R01 CA208205/CA/NCI NIH HHS/United States
- HHMI_/Howard Hughes Medical Institute/United States
- P30 CA014195/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources